NORDITROPIN 5mg/1.5ml NordiFlex Price

Overview

Welcome to Dwaey, specifically on NORDITROPIN 5mg/1.5ml NordiFlex Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Somatropin.
NORDITROPIN 5mg/1.5ml NordiFlex is available in the market in concentration 5mg (15 units)/1.5ml and in the form of Injection/Solution for.

NOVO NORDISK A/S is the producer of NORDITROPIN 5mg/1.5ml NordiFlex and it is imported from DENMARK, The most popular alternatives of NORDITROPIN 5mg/1.5ml NordiFlex are listed downward .

Mode Of Action

Somatropin is a synthetic human growth hormone of recombinant DNA origin. It stimulates skeletal and soft tissue growth by promoting cell division, amino acid uptake and protein synthesis. It also possesses both insulin-like and diabetogenic effects.

Indication

• Growth hormone deficiency
• HIV-associated wasting or cachexia
• Short bowel syndrome

Precaution

Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.

Side Effects

• Hypothyroidism
• peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics
• New onset type 2 diabetes mellitus
• Scoliosis
• Hypoglycemia
• Seizures
• Pancreatitis
• Exacerbation of psoriasis
• Hematuria
• Hematoma
• Leukemia
• Papilledema
• Arthralgia
• Hyperlipidemia
• Otitis media
• Ear disorders
• Respiratory Illness
• Urinary tract infection.

Contra indication

Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.